US 2006/0079510 A1 · Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis

Abstract

Method and composition for protecting tumorcidal lymphocytes including cytotoxic lymphocytes and NK cells from apoptosis and down regulation are provided. The method and composition include the administration of an effective amount of a PARP-1 inhibitor to a population of cytotoxic T lymphocytes and NK cells in the presence of monocytes or macrophages. In some embodiments, the method and composition additionally include the administration of a reactive oxygen metabolite (ROM) production or release inhibitory compound. Methods of treating cancer, viral diseases, and inflammatory diseases with a PARP-1 inhibitor are likewise provided.

Claims32

Dependent claims

A method of protecting cytotoxic T lymphocytes and NK cells in a subject, for the treatment of tumors, viral diseases or inflammatory diseases, comprising:

identifying a subject in need of cytotoxic T lymphocyte and NK cell protection;
administering to the subject an effective amount of a PARP-1 inhibitor effective to protect cytotoxic T lymphocytes and NK cells in the presence of monocytes or macrophages;
and
optionally administering an effective amount of an ROM production or release inhibitory compound.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

11/240,014Filed 29 Sep 2005

Priority

30 Sep 2004

Published

13 Apr 2006

Term ends

Not estimatedThe source records don’t support an estimate.

Classification7 codes

A61K 31/4709
Quinolines; Isoquinolines: non-condensed quinolines and containing further heterocyclic rings
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61P 29/00
Non-central analgesic, antipyretic or antiinflammatory agents
A61P 31/12
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics: antivirals

Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis

Life of this patent

Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis

Life of this patent

Abstract

Claims32